Aldurazyme®
Aldurazyme®: MPS I long-term enzyme replacement therapy
Access essential insights for MPS I specialists
Register or log in to access valuable resources about Aldurazyme®, a therapy designed to treat the non-neurological manifestations of MPS I. You'll receive the latest updates, educational materials1,10,14,15, and tools to enhance patient care. Sign up now to stay informed and make a difference in your practice.
References
- Aldurazyme Smpc Oct 2019.
- Early initiation of Aldurazyme® has been shown to influence the natural history of MPS I.
- O’Connor P, Wolinsky JS, Confavreux C, et al; for the TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-1303.
- Confavreux C, O’Connor P, Comi G, et al; for the TOWER Trial Group. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247-256.
- O’Connor P, Comi G, Freedman MS, et al; for the Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas. Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study. Neurology. 2016;86(10):920-930.
- Case reports of siblings initiating Aldurazyme at different ages highlight the benefits of early treatment in preventing and slowing disease progression.
- Aldurazyme has more than 17 years of established safety and tolerability.
- Clinical guidelines recommend maintaining regular infusions to manage MPS I symptoms effectively.
- Long-term commitment to Aldurazyme treatment is crucial for optimal patient outcomes.
- Regular assessments are key to monitoring patient response to Aldurazyme and ensuring optimal management of MPS I.
To continue reading confirm that you are a healthcare professional
Click login to continue